A prospective study on the use of magnesium sulfate in prevention and management of eclampsia with emphasis on adverse drug reactions

Heena Shah, B. M. Sattigeri, Shruti Brahmbhatt, Parul Singh, Devang Parikh, Ashok Kumar


Introduction: The hypertensive disorders in pregnancy are the leading causes of maternal and perinatal mortality. Management of preeclampsia and eclampsia remains controversial even today. Several drugs with different regimens are available at present. As a consequence; women are treated in various ways by different regimens.

Aim: Our work aimed to study the use of various magnesium sulfate regimens used in management of eclampsia in a tertiary care teaching rural hospital.

Methods: A prospective, observational, non-interventional study was carried out among the eclamptic patients admitted to obstetrics ward. After explaining the purpose and method of study, through the patient information sheet, patients willing to sign the informed consent form were enrolled for the study. Relevant data was gathered from their case files and by direct interview with the patients that were recorded in the case record form.

Results: Of the 35 cases of eclampsia recorded during the study period, we observed that all the patients were treated with Pritchard’s regimen of Magnesium Sulfate. It was noticed that there was improvement in all the patients with no adverse drug reactions recorded during the time of management.

Conclusion: Maternal and perinatal mortality can be reduced to major extent by prevention of eclampsia. Prompt diagnosis and institution of therapy by selecting an ideal anticonvulsant is essential as the maternal and perinatal mortality progressively rises with increase no of convulsions. Magnesium Sulfate is a potent anticonvulsant with mild antihypertensive activity with less adverse effects.



Eclampsia, Preeclampsia, Magnesium sulfate

Full Text:



World Health Organization. Trends in maternal mortality: 1990 to 2008. Geneva: WHO, 2010. Available at http://whqlidoc.who.int/publications.

F. Cunningham, Kenneth Leveno, Steven Bloom, John Hauth, Larry Gilstrap, Katharine Wenstrom. Williams Obstetrics. 22nd ed. London: Prentice Hall International Inc.; 2005.p.762-6,793.

Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet 2006;367:1066-74.

Lopez Jaramillop, Casas P, Serrano N. Preeclampsia from epidemiological observations to molecular mechanism. Branz J Med Bio Res 2006;34:1227-35.

Centre for Maternal and Child Enquries. Perinatal mortality 2010. Available at www.cemach.org.uk/getattachments/Perinatal-Mortality-2010.aspx.

Swain S, Ojha KN, Prakash A, et al. Maternal and perinatal mortality due to eclampsia. Indian Pediatr 1993;30:771-3.

National Institute for Health and Clinical Excellence. Hypertension in pregnancy. The Management of Hypertensive Disorders during Pregnancy. NICE Clinical Guideline 107, 2010. Available at www.nice.org.uk.

Duley L. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 1995;345:1455-63.

Bhatt A, Buriwala J. The evaluation of various anticonvulsant regimens in management of eclampsia. J Obstet Gynaecol India 1985;6:35.

Shaheen BM, Hassan L, Obaid M. Eclampsia, a major cause of maternal and perinatal mortality prospective analysis at a tertiary care hospital of Peshawar. J Pak Med Assoc 2003;53:346-50.

Dutta DC. Ed. Text book of Obstetrics including Perinatology and Contraception. 6th edition. Calcutta (INDIA): New central book agency LTD; 2006. p. 221,228-35.

Dewhurst’s text book of obstetrics and gynecology. 8th ed. Newyork: John Wiley and sons; 2012. p. 101-8.

Pritchard JA. Use of Magnesium Sulfate in severe preeclampsia- Eclampsia. J Repr Med 1979;23:107.

Pritchard JA. Standardized treatment in 154 cases of Eclampsia. Am J Obstet Gynecol 1975;123:543.

Sibai BM, Graham JM, McCubbin JH. A comparison of intravenous and intramuscular magnesium sulfate regimens in preeclampsia. Am J Obstet Gynecol 1984;150:728-33.